cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3535/yv4-3cc-bmg
title: Boloria aquilonaris (Stichel, 1908)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/ckt-vq2-bzn
title: Agriades Hübner, 1819

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/l3t-g3s-1vn
title: Denticucullus pygmina Haworth, 1809

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.6084/m9.figshare.28464258
title: A comprehensive exploration of adverse reactions to lapatinib: a disproportionate analysis based on the FAERS database

description: Lapatinib, an FDA-approved tyrosine kinase inhibitor, treats HER2+ advanced/metastatic breast cancer. This study comprehensively analyzed its adverse reaction profile using FDA Adverse Event Reporting System (FAERS) to guide clinical use. Adverse event (AE) reports for lapatinib from the second quarter of 2007 to the second quarter of 2024 in FAERS were analyzed using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multi-item Gamma Poisson Shrinkage (MGPS) and Bayesian Confidence Propagation Neural Network (BCPNN) to identify AE signals. Among 8300 AE reports, females (91.47%) and ages 40–59.9 (33.71%) were predominant. 20 system organ classifications (SOCs) were affected, with gastrointestinal disorders (ROR = 3.46) and skin disorders (ROR = 2.47) most significant. Based on the PT level, a total of 111 PTs were analyzed that met the four algorithms, including typical AEs such as diarrhea (<i>n</i> = 3410), vomiting (<i>n</i> = 856), and rash (<i>n</i> = 856), as well as some rare AEs that were not prompted by the drug inserts, such as neutropenia (<i>n</i> = 252), pericardial effusion (<i>n</i> = 43), lymphedema (<i>n</i> = 20). The majority of lapatinib-associated AEs had onset within 30 days (51%). Lapatinib has a generally favorable safety profile, but gastrointestinal toxicity and dermatotoxicity require close monitoring to prevent serious AEs.
DOI: 10.3535/h39-gxp-65t
title: Setina irrorella (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/mha-cse-xc8
title: Miltochrista miniata (Forster, 1771)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.6084/m9.figshare.28464258.v1
title: A comprehensive exploration of adverse reactions to lapatinib: a disproportionate analysis based on the FAERS database

description: Lapatinib, an FDA-approved tyrosine kinase inhibitor, treats HER2+ advanced/metastatic breast cancer. This study comprehensively analyzed its adverse reaction profile using FDA Adverse Event Reporting System (FAERS) to guide clinical use. Adverse event (AE) reports for lapatinib from the second quarter of 2007 to the second quarter of 2024 in FAERS were analyzed using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multi-item Gamma Poisson Shrinkage (MGPS) and Bayesian Confidence Propagation Neural Network (BCPNN) to identify AE signals. Among 8300 AE reports, females (91.47%) and ages 40–59.9 (33.71%) were predominant. 20 system organ classifications (SOCs) were affected, with gastrointestinal disorders (ROR = 3.46) and skin disorders (ROR = 2.47) most significant. Based on the PT level, a total of 111 PTs were analyzed that met the four algorithms, including typical AEs such as diarrhea (<i>n</i> = 3410), vomiting (<i>n</i> = 856), and rash (<i>n</i> = 856), as well as some rare AEs that were not prompted by the drug inserts, such as neutropenia (<i>n</i> = 252), pericardial effusion (<i>n</i> = 43), lymphedema (<i>n</i> = 20). The majority of lapatinib-associated AEs had onset within 30 days (51%). Lapatinib has a generally favorable safety profile, but gastrointestinal toxicity and dermatotoxicity require close monitoring to prevent serious AEs.
DOI: 10.3535/39c-exq-xyn
title: Denticucullus pygmina Haworth, 1809

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/yr6-n7r-s2x
title: Dasypolia (Dasypolia) templi Thunberg, 1792

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.6084/m9.figshare.25663262
title: Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis

description: Bimekizumab, a humanized monoclonal IgG1 antibody targeting both interleukin (IL)-17A and IL-17F, could be effective for treating Psoriatic arthritis (PsA). This study aimed to systematically evaluate the efficacy and safety of bimekizumab in the management of PsA. A comprehensive literature search by August 2023 was performed through PubMed, Embase, Cochrane Controlled Register of Trials, and ClinicalTrials.gov. investigating the efficacy or safety data of bimekizumab in the treatment of PsA. Data was pooled using the random-effects models. Egger tests were used to evaluate potential publication bias. A total of 4 RCTs, involving 892 PsA patients and 467 placebo controls, were included in this analysis. Bimekizumab significantly increased the rates of PASI75 and PASI100 compared with placebos [RR = 7.22, 95% CI (5.24, 9.94), p &lt; 0.001; RR = 10.12, 95% CI (6.00, 17.09), <i>p</i> &lt; 0.001]. The rate of overall adverse events was slightly higher in the bimekizumab group [RR = 1.42, 95% CI (1.05, 1.93) <i>p</i> = 0.023). However, there were fewer adverse severe drug reactions in the bimekizumab group compared to the placebo. Bimekizumab had a significant clinical benefit in managing PsA and an acceptable safety profile.
DOI: 10.6084/m9.figshare.25663262.v1
title: Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis

description: Bimekizumab, a humanized monoclonal IgG1 antibody targeting both interleukin (IL)-17A and IL-17F, could be effective for treating Psoriatic arthritis (PsA). This study aimed to systematically evaluate the efficacy and safety of bimekizumab in the management of PsA. A comprehensive literature search by August 2023 was performed through PubMed, Embase, Cochrane Controlled Register of Trials, and ClinicalTrials.gov. investigating the efficacy or safety data of bimekizumab in the treatment of PsA. Data was pooled using the random-effects models. Egger tests were used to evaluate potential publication bias. A total of 4 RCTs, involving 892 PsA patients and 467 placebo controls, were included in this analysis. Bimekizumab significantly increased the rates of PASI75 and PASI100 compared with placebos [RR = 7.22, 95% CI (5.24, 9.94), p &lt; 0.001; RR = 10.12, 95% CI (6.00, 17.09), <i>p</i> &lt; 0.001]. The rate of overall adverse events was slightly higher in the bimekizumab group [RR = 1.42, 95% CI (1.05, 1.93) <i>p</i> = 0.023). However, there were fewer adverse severe drug reactions in the bimekizumab group compared to the placebo. Bimekizumab had a significant clinical benefit in managing PsA and an acceptable safety profile.
DOI: 10.6084/m9.figshare.27254141.v1
title: Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the united states food and drug administration adverse event reporting system

description: Olaparib, niraparib, and rucaparib are the three primary poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors that are currently available in the market. Previous studies indicate different incidences of adverse events based on the PARP inhibitor or country. This study used data from the United States Food and Drug Administration Adverse Event Reporting System collected between January 2018 and December 2023. The data analyzed in this study involved patients receiving PARP inhibitors for treating ovarian cancer. A comparative analysis of the three PARP inhibitors was conducted using the reporting odds ratio (ROR) and the adjusted ROR (aROR) controlling for patient background differences. The aROR for niraparib was significant at &gt; 1.000, including platelet count decreased (<i>p</i> &lt; 0.001) and thrombocytopenia (<i>p</i> &lt; 0.001) when olaparib was set as the reference. Conversely, the aROR for niraparib was significant at &lt; 1.000, including anemia (<i>p</i> &lt; 0.001). Additionally, significant differences were observed in various adverse events for rucaparib. Moreover, significant differences were observed when comparing between countries. This study indicates that the types of adverse events may vary by PARP inhibitor and by country. These results will be beneficial in clinical practice.
DOI: 10.3535/24c-02m-hb3
title: Dasypolia (Dasypolia) templi Thunberg, 1792

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/yee-b28-vtq
title: Chersotis cuprea [Denis & Schiffermüller], 1775

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/hsq-zvg-vl8
title: Charanyca (Charanyca) trigrammica (Hufnagel, 1766)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.6084/m9.figshare.25624520
title: Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study

description: Immune checkpoint inhibitors (ICIs) show promise in cancer treatment, but recent cases highlight myositis as a serious complication. We did a retrospective study on drug safety using FAERS data up to Q3 2022, focusing on immune checkpoint inhibitors (ICIs) and myositis. We used IC and ROR to assess the association. Logistic regression in R 3.2.5 helped identify factors linked to fatal outcomes. We identified 558 cases of ICIs-associated myositis. Our study found a significant link between ICIs and myositis (ROR 15.54 [14.23–16.96], IC 3.79 [3.66–3.92], see Figure 1). Notably, myositis was more common in patients on ICI combination therapy compared to monotherapy (ROR 1.72 [1.39–2.11], IC 0.63 [0.30–0.93]). Age increased the risk of ICI-associated myositis and was also a factor in fatality (p = 0.011). Common accompanying adverse events included myocarditis (21.33%), severe myasthenia gravis (16.49%), and malignant neoplasm progression (8.06%). Fatal cases were more common when myositis was accompanied by myocarditis, severe myasthenia gravis, or malignant neoplasm progression. Clinicians must note the risk of ICI-associated myositis, especially dangerous in older patients or when combined with other issues like myocarditis or severe myasthenia gravis.
DOI: 10.6084/m9.figshare.25624520.v1
title: Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study

description: Immune checkpoint inhibitors (ICIs) hold promise as treatment options for various types of cancer. However, recent case reports have brought attention to myositis, a potentially life-threatening complication associated with ICIs. This study aims to assess the spectrum of myositis associated with ICIs, including its clinical features, risk factors for fatal cases, adverse events (AEs) accompanying ICIs-related myositis, and the risk of myositis in different populations in real-world settings. We conducted an observational, retrospective pharmacovigilance study using the Food and Drug Administration adverse event reporting system (FAERS) database, covering data from inception to quarter 3 of 2022. We employed the information component (IC) and reporting odds ratio (ROR) to evaluate the association between ICIs and myositis. Logistic regression analysis was performed to elucidate the factors related to fatal outcomes. All analyzes were conducted using R version 3.2.5. A total of 558 cases were identified as ICIs-associated myositis. Our study revealed a significant association between ICIs and myositis (ROR 15.54 [14.23-16.96], IC 3.79 [3.66-3.92], Figure 1). Notably, myositis was reported more frequently in patients treated with ICI combination therapy compared to those receiving ICI monotherapy (ROR 1.72 [1.39-2.11], IC 0.63 [0.30-0.93]). The risk of ICI-associated myositis increased with age, and age was also identified as a risk factor for fatality in cases of ICIs-associated myositis (<i>p</i> = 0.011). The most common accompanying AE observed were myocarditis (21.33%), followed by severe myasthenia gravis (16.49%) and malignant neoplasm progression (8.06%). The proportion of fatal cases was significantly higher for myositis accompanied by myocarditis, severe myasthenia gravis, and malignant neoplasm progression compared to non-fatal cases.Figure 1 Signal value of ICI associated myositis (ICIs: immune checkpoint inhibitors, N: number; ROR: reporting odds ratio; IC: information component) Signal value of ICI associated myositis (ICIs: immune checkpoint inhibitors, N: number; ROR: reporting odds ratio; IC: information component) Clinicians should be aware of the potential for ICI-associated myositis, as it can be particularly life-threatening, especially in elderly patients or when it occurs concurrently with other AEs such as myocarditis or severe myasthenia gravis.
DOI: 10.6084/m9.figshare.25624520.v2
title: Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study

description: Immune checkpoint inhibitors (ICIs) show promise in cancer treatment, but recent cases highlight myositis as a serious complication. We did a retrospective study on drug safety using FAERS data up to Q3 2022, focusing on immune checkpoint inhibitors (ICIs) and myositis. We used IC and ROR to assess the association. Logistic regression in R 3.2.5 helped identify factors linked to fatal outcomes. We identified 558 cases of ICIs-associated myositis. Our study found a significant link between ICIs and myositis (ROR 15.54 [14.23–16.96], IC 3.79 [3.66–3.92], see Figure 1). Notably, myositis was more common in patients on ICI combination therapy compared to monotherapy (ROR 1.72 [1.39–2.11], IC 0.63 [0.30–0.93]). Age increased the risk of ICI-associated myositis and was also a factor in fatality (p = 0.011). Common accompanying adverse events included myocarditis (21.33%), severe myasthenia gravis (16.49%), and malignant neoplasm progression (8.06%). Fatal cases were more common when myositis was accompanied by myocarditis, severe myasthenia gravis, or malignant neoplasm progression. Clinicians must note the risk of ICI-associated myositis, especially dangerous in older patients or when combined with other issues like myocarditis or severe myasthenia gravis.
DOI: 10.6084/m9.figshare.27194039
title: Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA Adverse Event Reporting System database

description: Rufinamide (RUF) is an antiepileptic drug recently introduced for managing seizures in Lennox-Gastaut syndrome (LGS), but its adverse reactions are not well understood. This study aims to evaluate RUF’s safety profile using data from the FDA Adverse Event Reporting System (FAERS). Disproportionality analysis was conducted to assess RUF-associated adverse drug events (ADEs), using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma-Poisson shrinker (MGPS). We collected 338 ADE reports related to RUF. Nervous system disorders were the most frequently reported signals, and several new ADEs were detected, including atonic seizures, sudden unexplained death in epilepsy, seizure clusters, multi-drug resistance, and Stevens-Johnson syndrome. Nearly half of the ADEs in pediatric patients were psychological or neurological. Disproportionality analysis within 4 weeks of treatment showed high RORs for QT shortening, sudden death, and atonic seizures. Our study revealed prospective signals of new ADEs linked to RUF as well as revealed that both prescribers and patients were more conscious of the risks involved in its clinical use.
DOI: 10.6084/m9.figshare.27194039.v2
title: Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA Adverse Event Reporting System database

description: Rufinamide (RUF) is an antiepileptic drug recently introduced for managing seizures in Lennox-Gastaut syndrome (LGS), but its adverse reactions are not well understood. This study aims to evaluate RUF’s safety profile using data from the FDA Adverse Event Reporting System (FAERS). Disproportionality analysis was conducted to assess RUF-associated adverse drug events (ADEs), using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma-Poisson shrinker (MGPS). We collected 338 ADE reports related to RUF. Nervous system disorders were the most frequently reported signals, and several new ADEs were detected, including atonic seizures, sudden unexplained death in epilepsy, seizure clusters, multi-drug resistance, and Stevens-Johnson syndrome. Nearly half of the ADEs in pediatric patients were psychological or neurological. Disproportionality analysis within 4 weeks of treatment showed high RORs for QT shortening, sudden death, and atonic seizures. Our study revealed prospective signals of new ADEs linked to RUF as well as revealed that both prescribers and patients were more conscious of the risks involved in its clinical use.
DOI: 10.3535/7v6-5xl-yzt
title: Charissa obscurata ([Denis & Schiffermüller], 1775)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/ktm-m4e-6n5
title: Speyeria aglaja (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.6084/m9.figshare.27194039.v1
title: Disproportionality analysis of the safety profile of rufinamide in the real world: an evaluation of the FDA adverse event reporting system database

description: The antiepileptic drug rufinamide (RUF), was recently introduced to alleviate seizures in patients with Lennox-Gastaut syndrome (LGS). However, little is known about its adverse reactions. The objective of this study is to probe, assess, and share evidence on RUF safety profiles via data from the FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis of RUF-associated adverse drug events (ADEs) was assessed through the calculation of the reporting odds (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma-Poisson shrinker (MGPS). A total of 338 ADE reports related to RUF were collected. Nervous system disorders were the most frequently reported positive signals. Notably, new unexpectedly significant ADEs were detected. Among them, atonic seizures, sudden unexplained death with epilepsy, seizure clusters, multiple-drug resistance, Stevens‒Johnson syndrome, and other possible novel signals deserve awareness. An examination of age-specific differences in the detected signals indicated that nearly half of the ADEs observed in children receiving RUF were categorized as psychological or neurological system diseases. Our disproportionality analysis of ADEs within 4 weeks of treatment revealed high RORs for electrocardiogram Qt shortened, sudden unexplained death in patients with epilepsy, and atonic seizures. Our study revealed prospective signals of new ADEs linked to RUF as well as revealed that both prescribers and patients were more conscious of the risks involved in its clinical use.
DOI: 10.3535/b44-6t6-rxn
title: Staurophora celsia Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/kbk-e6m-63l
title: Setina irrorella (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/1yz-al7-42e
title: Nycteola degenerana (Hübner, 1799)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/bj2-0lj-ath
title: Agriphila tristellus [Denis & Schiffermüller], 1775

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/sy1-kj5-mm5
title: Xanthia (Xanthia) togata Esper

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/aeq-90v-am7
title: Staurophora celsia Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/yly-cyf-ajj
title: Polychrysia moneta (Fabricius, 1787)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/4mv-33f-y0h
title: Lycaena virgaureae (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/c3p-f1z-z33
title: Lycaena virgaureae (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/q5g-f8x-ydh
title: Staurophora celsia Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/y7z-2y1-54c
title: Eudonia sudetica Zeller, 1839

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/w6h-my8-kq9
title: Staurophora celsia Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/954-72v-eb4
title: Deilephila elpenor Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/a4e-m55-wby
title: Callophrys rubi (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/539-4ne-gq6
title: Hypena proboscidalis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/hh3-9w0-5w9
title: Staurophora celsia Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/3mz-b8g-8tl
title: Hypena proboscidalis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/g2h-v2n-hbz
title: Speyeria aglaja (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/h9v-jxy-zay
title: Charanyca (Charanyca) trigrammica (Hufnagel, 1766)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/2sh-bcw-9vf
title: Euplexia lucipara (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/rvk-a4n-8sb
title: Chersotis cuprea [Denis & Schiffermüller], 1775

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/6vm-j6t-sn1
title: Speyeria aglaja (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/hfb-3vc-hkq
title: Boloria aquilonaris (Stichel, 1908)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/51e-z6b-zt6
title: Euclidia (Euclidia) glyphica Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/h93-grw-2t6
title: Coscinia cribraria (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.